CL2016001160A1 - Dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende un núcleo de matriz polimérica con agente terapéutico y un revestimiento polimérico que rodea a la matriz y el dispositivo se forma de un segmento anular con un diámetro de sección transversal que varía de 0,10-0,80 mm. - Google Patents
Dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende un núcleo de matriz polimérica con agente terapéutico y un revestimiento polimérico que rodea a la matriz y el dispositivo se forma de un segmento anular con un diámetro de sección transversal que varía de 0,10-0,80 mm.Info
- Publication number
- CL2016001160A1 CL2016001160A1 CL2016001160A CL2016001160A CL2016001160A1 CL 2016001160 A1 CL2016001160 A1 CL 2016001160A1 CL 2016001160 A CL2016001160 A CL 2016001160A CL 2016001160 A CL2016001160 A CL 2016001160A CL 2016001160 A1 CL2016001160 A1 CL 2016001160A1
- Authority
- CL
- Chile
- Prior art keywords
- polymeric coating
- drug delivery
- therapeutic agent
- release drug
- groove
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/005—Templates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se divulga un dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende: (a) Un núcleo de matriz polimérica en el que se mezcla al menos un agente terapéutico y (b) Un revestimiento polimérico que rodea completamente dicho material de matriz polimérica, En el que dicho núcleo de matriz polimérica y el revestimiento polimérico son insolubles e inertes en los líquidos oculares, y en el que dicho dispositivo intraocular de suministro de fármacos de liberación sostenida se forma de un segmento anular compatible, que tiene un diámetro de sección transversal que varía de 0,10 a 0,80 mm y en el que el grado de reticulación en el polímero seleccionado para el revestimiento polimérico regula las velocidades de liberación del fármaco desde el dispositivo intraocular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192889 | 2013-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001160A1 true CL2016001160A1 (es) | 2017-03-17 |
Family
ID=49584627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001160A CL2016001160A1 (es) | 2013-11-14 | 2016-05-13 | Dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende un núcleo de matriz polimérica con agente terapéutico y un revestimiento polimérico que rodea a la matriz y el dispositivo se forma de un segmento anular con un diámetro de sección transversal que varía de 0,10-0,80 mm. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9999595B2 (es) |
| EP (2) | EP3068372B1 (es) |
| JP (1) | JP6602761B2 (es) |
| KR (1) | KR20160085870A (es) |
| CN (1) | CN105792812B (es) |
| AU (1) | AU2014350095B9 (es) |
| BR (1) | BR112016010638B1 (es) |
| CA (1) | CA2929684C (es) |
| CL (1) | CL2016001160A1 (es) |
| EA (1) | EA032183B1 (es) |
| ES (2) | ES2864274T3 (es) |
| HK (1) | HK1223271A1 (es) |
| IL (1) | IL245405A0 (es) |
| MA (1) | MA39111A1 (es) |
| MX (1) | MX2016006142A (es) |
| TN (1) | TN2016000162A1 (es) |
| WO (1) | WO2015071427A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10507101B2 (en) | 2014-10-13 | 2019-12-17 | W. L. Gore & Associates, Inc. | Valved conduit |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| US11406533B2 (en) | 2017-03-17 | 2022-08-09 | W. L. Gore & Associates, Inc. | Integrated aqueous shunt for glaucoma treatment |
| CA3087238A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| AU2019275409A1 (en) | 2018-05-24 | 2020-07-16 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| AU2019310003A1 (en) | 2018-07-23 | 2021-02-04 | SpyGlass Pharma, Inc. | Ophthalmic device for drug delivery |
| US11678983B2 (en) | 2018-12-12 | 2023-06-20 | W. L. Gore & Associates, Inc. | Implantable component with socket |
| MX2021015760A (es) | 2019-06-27 | 2022-04-06 | Layerbio Inc | Sistemas de administracion de medicamentos de dispositivos oculares. |
| US11399977B2 (en) | 2020-06-04 | 2022-08-02 | SpyGlass Pharma, Inc. | Ophthalmic implant system for drug delivery |
| US20230149298A1 (en) * | 2021-11-17 | 2023-05-18 | Celanese Eva Performance Polymers Llc | Implantable Device for Treating an Inflammatory Eye Condition |
| CN114224822B (zh) * | 2022-01-28 | 2023-07-14 | 复旦大学附属眼耳鼻喉科医院 | 一种眼部缓释给药植入物及其制造方法 |
| EP4233836A1 (en) | 2022-02-24 | 2023-08-30 | Eyed Pharma | Intraocular drug delivery device comprising an eyelet |
| WO2024020505A2 (en) * | 2022-07-22 | 2024-01-25 | SpyGlass Pharma, Inc. | Intraocular drug delivery systems and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3416530A (en) | 1966-03-02 | 1968-12-17 | Richard A. Ness | Eyeball medication dispensing tablet |
| US3618604A (en) | 1969-06-09 | 1971-11-09 | Alza Corp | Ocular insert |
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US4014335A (en) | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| US4144317A (en) | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
| US4668506A (en) | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
| US4959217A (en) * | 1986-05-22 | 1990-09-25 | Syntex (U.S.A.) Inc. | Delayed/sustained release of macromolecules |
| US4718905A (en) * | 1986-08-13 | 1988-01-12 | Freeman Jerre M | Haptic element using ion beam implantation for an intraocular lens |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5178635A (en) | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5928282A (en) * | 1997-06-13 | 1999-07-27 | Bausch & Lomb Surgical, Inc. | Intraocular lens |
| US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| FR2787991B1 (fr) * | 1998-12-31 | 2001-05-25 | Medicale De Prec S M P Sa Soc | Dispositif pour traiter la presbytie ou autre affection oculaire |
| GB2399753B (en) * | 2002-01-18 | 2006-04-19 | Michael E Snyder | Method of making a sustained release ophthalmological device |
| FR2844703B1 (fr) * | 2002-09-25 | 2005-07-08 | Alain Nicolas Gilg | Dispositif intraoculaire pour restaurer l'accommodation de l'oeil atteint de presbytie |
| US20090018650A1 (en) * | 2003-06-19 | 2009-01-15 | Boxer Wachler Brian S | Ophthalmological zonular stretch segment for treating presbyopia |
| WO2006110487A1 (en) * | 2005-04-08 | 2006-10-19 | Surmodics, Inc. | Sustained release implants for subretinal delivery |
| WO2009140246A2 (en) * | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| BRPI0918253A2 (pt) * | 2008-09-12 | 2015-12-15 | Critical Pharmaceuticals Ltd | aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele |
| WO2010101758A1 (en) | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | Peri-corneal drug delivery device |
| CN102905688B (zh) * | 2010-04-06 | 2015-11-25 | 阿勒根公司 | 用于前房内药物递送的缓释储库式植入物 |
-
2014
- 2014-11-14 CA CA2929684A patent/CA2929684C/en active Active
- 2014-11-14 ES ES19165620T patent/ES2864274T3/es active Active
- 2014-11-14 AU AU2014350095A patent/AU2014350095B9/en active Active
- 2014-11-14 EA EA201690967A patent/EA032183B1/ru not_active IP Right Cessation
- 2014-11-14 EP EP14809301.6A patent/EP3068372B1/en active Active
- 2014-11-14 TN TN2016000162A patent/TN2016000162A1/en unknown
- 2014-11-14 BR BR112016010638-5A patent/BR112016010638B1/pt active IP Right Grant
- 2014-11-14 US US15/034,869 patent/US9999595B2/en active Active
- 2014-11-14 EP EP19165620.6A patent/EP3566693B1/en active Active
- 2014-11-14 MA MA39111A patent/MA39111A1/fr unknown
- 2014-11-14 CN CN201480062417.9A patent/CN105792812B/zh active Active
- 2014-11-14 ES ES14809301T patent/ES2740352T3/es active Active
- 2014-11-14 WO PCT/EP2014/074644 patent/WO2015071427A1/en active Application Filing
- 2014-11-14 KR KR1020167015621A patent/KR20160085870A/ko not_active Application Discontinuation
- 2014-11-14 MX MX2016006142A patent/MX2016006142A/es unknown
- 2014-11-14 JP JP2016531690A patent/JP6602761B2/ja active Active
-
2016
- 2016-05-02 IL IL245405A patent/IL245405A0/en unknown
- 2016-05-13 CL CL2016001160A patent/CL2016001160A1/es unknown
- 2016-09-29 HK HK16111409.4A patent/HK1223271A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2929684A1 (en) | 2015-05-21 |
| KR20160085870A (ko) | 2016-07-18 |
| MA39111A1 (fr) | 2017-04-28 |
| JP2016537370A (ja) | 2016-12-01 |
| ES2864274T3 (es) | 2021-10-13 |
| AU2014350095B9 (en) | 2019-09-12 |
| BR112016010638B1 (pt) | 2023-01-31 |
| HK1223271A1 (zh) | 2017-07-28 |
| CN105792812A (zh) | 2016-07-20 |
| IL245405A0 (en) | 2016-06-30 |
| CN105792812B (zh) | 2020-10-23 |
| CA2929684C (en) | 2022-02-22 |
| EA032183B1 (ru) | 2019-04-30 |
| AU2014350095B2 (en) | 2019-08-29 |
| TN2016000162A1 (en) | 2017-10-06 |
| EA201690967A1 (ru) | 2016-10-31 |
| ES2740352T3 (es) | 2020-02-05 |
| MX2016006142A (es) | 2016-12-09 |
| EP3068372B1 (en) | 2019-05-08 |
| US20160287513A1 (en) | 2016-10-06 |
| US9999595B2 (en) | 2018-06-19 |
| JP6602761B2 (ja) | 2019-11-06 |
| WO2015071427A1 (en) | 2015-05-21 |
| EP3566693B1 (en) | 2021-02-17 |
| EP3068372A1 (en) | 2016-09-21 |
| BR112016010638A2 (es) | 2017-08-08 |
| AU2014350095A1 (en) | 2016-06-09 |
| EP3566693A1 (en) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001160A1 (es) | Dispositivo intraocular de suministro de fármacos de liberación sostenida configurado para el surco de los ojos, que comprende un núcleo de matriz polimérica con agente terapéutico y un revestimiento polimérico que rodea a la matriz y el dispositivo se forma de un segmento anular con un diámetro de sección transversal que varía de 0,10-0,80 mm. | |
| CL2016001041A1 (es) | Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable. | |
| CL2018002720A1 (es) | Método y aparato para suministro de agentes terapéuticos. | |
| CO2020006262A2 (es) | Tubería de alta presión con elementos pultruidos y procedimiento para producir la misma. | |
| NI201800038S (es) | Dispositivo de administración de medicamento intranasal | |
| BR112018003110A2 (pt) | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos | |
| CU20160164A7 (es) | Un nanocomplejo micelar | |
| PE20170167A1 (es) | Conjunto de cable de fibra optica para terminacion de un cable de fibra optica y metodos de fabricacion de los mismos | |
| BR112015019546A2 (pt) | implante de distribuição de drogas prolongado | |
| MD20160079A2 (ro) | Sistem de livrare a medicamentului | |
| BR102015017380A2 (pt) | dispositivo para a reticulação do tecido do olho, e, composição farmacêutica | |
| AR104745A1 (es) | Sistema de césped artificial | |
| EP4173615A3 (en) | Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems | |
| CO2017005624A2 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| MX2017012400A (es) | Metodo para la fabricacion de material de fibra biodegradable que contiene farmaco mediante electrohilado. | |
| BR112017025325A2 (pt) | compósitos elastoméricos termicamente condutores | |
| EA201791005A1 (ru) | Улучшенные антитела против il-6 | |
| MX2016014622A (es) | Sistemas de suministro de medicamentos y metodos de uso relacionados. | |
| AR099168A1 (es) | Filamentos de césped artificial y artículos hechos de los mismos | |
| AR106133A1 (es) | Métodos para el tratamiento de la epilepsia | |
| CY1123720T1 (el) | Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος | |
| AR100231A1 (es) | Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea | |
| BR112018006870A2 (pt) | nanopartículas terapêuticas que compreendem um agente terapêutico e métodos para a produção e o uso das mesmas | |
| MX2020003667A (es) | Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona. | |
| BR112018012014A2 (pt) | materiais óticos de nanoemulsão |